Business Description
Moleculin Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US60855D1019
Description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 41.03 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.4 | |||||
| 3-Year EPS without NRI Growth Rate | 21.3 | |||||
| 3-Year FCF Growth Rate | 23.6 | |||||
| 3-Year Book Growth Rate | -20.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.57 | |||||
| 9-Day RSI | 31 | |||||
| 14-Day RSI | 37.34 | |||||
| 6-1 Month Momentum % | -10.79 | |||||
| 12-1 Month Momentum % | -37.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.86 | |||||
| Quick Ratio | 3.86 | |||||
| Cash Ratio | 3.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -42.5 | |||||
| Shareholder Yield % | -38.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -74.66 | |||||
| ROA % | -63.79 | |||||
| ROIC % | -249.36 | |||||
| ROC (Joel Greenblatt) % | -4284.41 | |||||
| ROCE % | -71.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 0.71 | |||||
| EV-to-EBIT | 0.4 | |||||
| EV-to-Forward-EBIT | -6.27 | |||||
| EV-to-EBITDA | 0.41 | |||||
| EV-to-Forward-EBITDA | -7.05 | |||||
| EV-to-FCF | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 0.75 | |||||
| Price-to-Net-Cash | 0.93 | |||||
| Earnings Yield (Greenblatt) % | 250 | |||||
| FCF Yield % | -219.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moleculin Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -14.172 | ||
| Beta | 1.61 | ||
| Volatility % | 77.74 | ||
| 14-Day RSI | 37.34 | ||
| 14-Day ATR (€) | 0.03112 | ||
| 20-Day SMA (€) | 6.45 | ||
| 12-1 Month Momentum % | -37.23 | ||
| 52-Week Range (€) | 3.989999 - 12.749999 | ||
| Shares Outstanding (Mil) | 2.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moleculin Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moleculin Biotech Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Moleculin Biotech Inc Frequently Asked Questions
What is Moleculin Biotech Inc(FRA:MOL)'s stock price today?
The current price of FRA:MOL is €6.45. The 52 week high of FRA:MOL is €12.75 and 52 week low is €3.99.
When is next earnings date of Moleculin Biotech Inc(FRA:MOL)?
The next earnings date of Moleculin Biotech Inc(FRA:MOL) is 2024-05-15 Est..
Does Moleculin Biotech Inc(FRA:MOL) pay dividends? If so, how much?
Moleculin Biotech Inc(FRA:MOL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers